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We investigated the protective role of Withania somnifera leaf extract (WSLEt) on isoproterenol- (ISO-) induced myocardial
infarction (MI) in rats. Subcutaneous injection of ISO (85mg/kg body weight (b.w.)) administered to rats for two consecutive days
caused a significant increase in cardiac troponin I (cTnI) levels and serum lipid profiles, as well as the activities of some marker
enzymes. In addition to these diagnosticmarkers, there were increased levels of lipid peroxidation (LPO) and decreased activities of
enzymatic antioxidants (superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GRx), and glutathione-
S-transferase (GST)) in the myocardium. However, oral pretreatment (100mg/kg b.w.) withWSLEt for 4 weeks elicited a significant
cardioprotective activity by lowering the levels of cTnI, lipid profiles, and marker enzymes. The levels of LPO products were also
significantly decreased. Elevated activities of antioxidant enzymes were also observed in rats pretreated with WSLEt. As further
confirmed histopathologically, our findings strongly suggest that the cardioprotective effect ofWSLEt onmyocardium experiencing
ISO-induced oxidative damage may be due to an augmentation of the endogenous antioxidant system and an inhibition of LPO in
the myocardial membrane. We conclude that WSLEt confers some protection against oxidative damage in ISO-induced MI in rats.
1. Introduction
Withania somnifera (Solanaceae), also known as “ashwa-
gandha” or “winter cherry,” is one of the most valuable
herbs in the traditional Indian systems of medicine [1]. The
plant is utilized in more than 100 formulations in Ayurveda,
Unani, and Siddha [2]. It is described as an herbal tonic and
health food in the famous book of Vedas and is considered
akin to an “Indian Ginseng” in the traditional Indian system
of healing [3]. The ethnopharmacological properties of the
plant include adaptogenic, antisedative, and anticonvulsive
activities. The plant is used to treat various neurological
disorders, geriatric debilities, arthritis, stress, and behavior-
related problems [4]. W. somnifera contains a variety of
nutrients and phytochemicals and is therefore also used as a
dietary supplement. It has been reported that all of the major
parts of W. somnifera, such as the roots, fruits, and leaves,
provide potential benefits for human health because of their
high polyphenol contents and antioxidant activities [5].
Myocardial infarction (MI) is a common presentation of
ischemic heart disease (IHD). MI remains the major cause of
death in the developedworld and is amajor pathological issue
worldwide despite rapid advancementsmade in the treatment
of coronary artery diseases (CAD) [6]. It occurs as a result
of increased myocardial metabolic demand and decreased
supply of oxygen and nutrients via the coronary circulation
to themyocardium, leading to cell injury; it is one of themost
lethal manifestations of cardiovascular diseases (CVD) [7].
MI continues to be a major public health problem, not only
in western countries but also increasinglymore in developing
countries, where it contributes significantly to mortality [8].
According to theWorld Health Organization,MI is predicted
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to be themajor cause of death in the world by the year of 2020
[9].
Isoproterenol [1–(3, 4–dihydroxyphenyl)–2–isopropyl-
aminoethanol hydrochloride (ISO)] is a synthetic cate-
cholamine and 𝛽-adrenergic agonist that is an important
regulator of myocardial contractility and metabolism, thus
serving as the key element of a standard model for the
study of potentially beneficial effects of numerous drugs
on cardiac function [7]. ISO induces cardiac necrosis by
several mechanisms, including increased oxygen consump-
tion, poor oxygen utilization, increased calcium overload and
accumulation, altered myocardial cell metabolism, increased
myocardial cAMP levels, deranged electrolyte milieu, altered
membrane permeability, intracellular acidosis, and increased
levels of lipid peroxides [10]. The pathophysiological and
morphological aberrations produced in the heart of the
myocardial necrotic rat model are comparable with those
taking place in humanMI.The variousmechanisms proposed
to explain ISO-induced cardiotoxicity include the generation
of highly cytotoxic free radicals through the autooxidation
of catecholamines, which has been implicated as one of the
important causative factors [11].
Oxidation of catecholamine forms quinoid compounds
giving rise to the production of superoxide anions and,
subsequently, hydrogen peroxide, which, in the presence
of iron, forms highly reactive hydroxyl radicals and causes
protein, lipid, and DNA damage and increased MI size [12].
In addition, excessive formation of free radicals may result
in the loss of function and integrity of myocardial mem-
branes [13]. These free radicals may attack polyunsaturated
fatty acids (PUFAs) within the membranes, forming peroxyl
radicals. These radicals can then attack adjacent fatty acids,
causing a chain reaction of lipid peroxidation (LPO). The
lipid hydroperoxide end products are also harmful and may
contribute to further tissue and organ damage [14].
In recent years, long-term prevention of CVD is asso-
ciated with the consumption of fresh fruits, vegetables, or
plants rich in natural antioxidants. As a result, there has
been considerable interest in research on natural bioactive
compounds, with a generally accepted view that natural
products are superior in terms of efficacy and safety when
compared to their synthetic analogs [15]. Medicinal plants
constitute an important source of active natural products that
differ widely in terms of structure and biological properties
and play an important role in the protection against various
human diseases including CVD [16].
A previous study reported thatW. somnifera, particularly
its leaves, has remarkable antioxidant properties [1].W. som-
nifera leaves have been reported to contain higher amounts
of polyphenols and flavonoids when compared to the roots
and fruits [5]. To date, many epidemiological studies have
demonstrated the effectiveness of phenolics and flavonoids as
antitumor, anti-inflammatory agent or in reducing the risk of
cardiovascular diseases [17]. Most importantly,W. somnifera
leaves contain higher levels of catechin, which belongs to
the flavonoid family, when compared to other parts of the
plant [5]. Some previous studies have strongly suggested
that catechin reduces the risk of IHD [18, 19]. To date,
there is no or little available data on the potential medicinal
properties of W. somnifera leaves, since most studies tend to
focus on W. somnifera roots [7, 20]. Considering the more
robust antioxidant potential and higher catechin content of
W. somnifera leaves, we were interested in investigating the
effect of W. somnifera leaves on oxidative stress-induced
cardiac injury. In this study, the cardioprotective effect ofW.
somnifera leaf extract (WSLEt) was investigated in relation to
cardiac marker enzymes, lipid peroxides, and the antioxidant
enzyme defense system.
2. Materials and Methods
2.1. Experimental Animals. The experiments were conducted
according to ethical guidelines as approved by the Bangladesh
Association for Laboratory Animal Science. Adult male
Wistar Albino rats (𝑛 = 40) (140–160 g) were bred and
reared in the animal house facility of the Department of
Biochemistry and Molecular Biology, Jahangirnagar Univer-
sity, at a constant room temperature of 23 ± 2∘C, and in
an environment with humidity ranging between 40% and
70%. The rats were housed in plastic cages (with hard wood
chips for bedding) and received a natural 12 h day-night cycle.
The rats were provided with a standard laboratory pellet diet
and water ad libitum. The pellet diet consisted of 56.17%
carbohydrate, 22.02% crude protein, 4.25% crude oil, 3.25%
crude fibre, 2.46% glucose, 0.8% calcium, 0.6% phosphorus,
and 1.8% vitamins.
2.2. Drugs and Chemicals. The assay kit used for the estima-
tion of cardiac troponin I (cTnI) levels was purchased from
JAJ International, Inc., USA. Other assay kits for the mea-
surement of creatine kinase (CK-MB), lactate dehydrogenase
(LDH), aspartate transaminase (AST) and alanine transam-
inase (ALT), TC (total cholesterol), TGs (triglycerides),
and high-density lipoprotein-cholesterol (HDL-C) were all
purchased from Stanbio Laboratory, USA. The assay kits for
superoxide dismutase (SOD), glutathione peroxidase (GPx),
glutathione reductase (GRx), and glutathione-S-transferase
(GST) were purchased from Abnova Corporation, Taiwan.
ISO and 1,1,3,3-tetraethoxy propane were purchased from
Nacalai Tesque, Inc., Kyoto, Japan. All of the chemicals and
reagents used in this study were of analytical grade.
2.3. Sample Collection and Extraction. W. somnifera leaves
were collected from the Gaibanda Samriddhi Project, HEL-
VETAS Swiss Inter Cooperation-Bangladesh, in July, 2013,
and were authenticated by a botanist (Professor M. Shah
Alam, Department of Botany, Rajshahi University, Rajshahi
6205, Bangladesh). The collected leaves of the medicinal
plant were cleaned and then air-dried in the shade for 7
days before being ground to a fine powder by a blender
(CM/L7360065, Jaipan,Mumbai, India).The fine powder was
used to prepare a 5% ethanolic extract (5 g ofW. somnifera leaf
powder added to a final volume of 100mL of a 70% ethanol
solution) in the dark so as to avoid reactions in solution
that may occur in the presence of light. The solution was
shaken in a shaker for 72 h at room temperature. Then, the
solution was filtered and dried in a rotary evaporator (Buchi,
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Figure 1: Schematic representation of experimental design of the study.
Tokyo, Japan) under reduced pressure (100 psi) at a controlled
temperature (40∘C).The dried extract was collected and then
finally preserved at −20∘C for subsequent in vivo studies.
Only the required amount was withdrawn from refrigerator
to ensure the stability of the extract.
2.4. Experimental Design. After a week-long acclimation
period, the animals were randomly divided into 4 groups (10
rats in each group) (Figure 1).
Sham. Animals received only distilled water (2mL/kg) for 4
weeks andwere then treated by normal saline injection (1mL)
for 2 days (on the 29th and 30th days).
WSLEt + Sham. Animals were pretreated with WSLEt
(100mg/kg) for 4 weeks at 24 hr interval and then treated by
normal saline injection (1mL) for 2 days (on the 29th and
30th days).
WSLEt + ISO. Animals were pretreated with WSLEt
(100mg/kg) for 4 weeks at 24 hr interval and then treated by
ISO injection (85mg/kg) for 2 days (on the 29th and 30th
days).
ISO. Animals received only distilled water (2mL/kg) for 4
weeks and were then treated by ISO injection (85mg/kg) for
2 days (on the 29th and 30th days).
2.5. Induction of ExperimentalMI. ISO (85mg)was dissolved
in normal saline (1mL) andwas subcutaneously (s.c.) injected
into rats (85mg/kg) at an interval of 24 h for 2 days to induce
experimentalMI.The choice of ISO dose was based on a pilot
study for ISO dose fixation and on the results of a previous
study [21]. The WSLEt dosage was based on previous studies
[7, 22].
During the experimental period, the rats’ body weights
were recorded regularly and the doses were modulated
accordingly. At 48 h after the first ISO injection, all animals
were sacrificed by decapitation. Blood samples (3mL) were
collected and serum samples were separated by centrifu-
gation. Immediately following blood collection, the heart
samples were separated from surrounding tissues and were
washed twice with ice cold phosphate-buffered saline. The
sampleswere then homogenized in phosphate buffer (25mM,
pH 7.4) using a tissue homogenizer (F 12520121, Omni
International, Kennesaw, USA) to produce an approximately
10% w/v homogenate. The homogenate was centrifuged at
1,700 rpm for 10min, and the supernatant was collected
and stored at −20∘C for subsequent biochemical analyses.
Some of the heart samples were stored in 10% formalin for
histopathological examination.
2.6. Serum Biochemical Analysis. An enzyme immunoassay
kit was employed for the determination of cTnI in serum
samples using an ELISA micro-plate reader (digital and
analog system RS232, Das, Italy). Standard assay kits were
employed to determine the levels of CK-MB, LDH, AST, ALT,
TC, TGs, and HDL-C in serum samples using a PD-303S
Spectrophotometer (APEL, Japan). Serum VLDL-C levels
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Table 1: Changes in the body and heart weights in different groups of rats.
Parameters Group
Sham WSLEt + Sham WSLEt + ISO ISO
Initial body weight (g) 143.70 ± 24.16a 146.71 ± 15.99a 141.00 ± 23.43a 148.63 ± 19.91a
Final body weight (g) 164.82 ± 19.28a 175.00 ± 6.36a 169.75 ± 16.64a 172.00 ± 21.59a
Body weight gain (g) 21.12a 28.29a 28.75a 23.37a
Absolute heart weight (g) 0.62 ± 0.03a 0.66 ± 0.03a 0.73 ± 0.02b 0.97 ± 0.06c
Relative heart weight (g/100 g) 0.39 ± 0.02a 0.39 ± 0.01a 0.49 ± 0.02b 0.57 ± 0.04c
Results are expressed as mean values ± SD; 𝑛 = 10. a,b,cValues in the same row that do not share superscript letters (a, b, c) differ significantly at 𝑝 < 0.05.
were calculated based on a formula provided by Friedewald
[23]:
VLDL-C = TG
5
. (1)
2.7. Biochemical Analysis in Heart Tissue. Malondialdehyde
(MDA) levels were assayed for LPO products in the heart
tissues. MDA, which is also referred to as thiobarbituric
acid-reactive substance (TBARS), was measured according
to the method published by Ohkawa et al. [24]. Briefly,
0.2mL of tissue homogenate, 0.2mL of 8.1% sodium dodecyl
sulphate (SDS), 1.5mL of 20% acetic acid, and 1.5mL of
8% TBA were mixed. The mixture was supplemented up to
4mL with distilled water and was heated at 95∘C in a water
bath for 60min. After incubation, the tubes were cooled to
room temperature and the final volume was increased to
5mL in each tube. A butanol : pyridine (15 : 1) mixture (5mL)
was added and the contents were vortexed thoroughly for
2min. After centrifugation (3,000 rpm) for 10min, the upper
organic layer was aspirated, and its absorbance was read at
532 nm against the blank.The levels of TBARSwere expressed
as nmol of MDA per mg of protein.
The heart tissue homogenate was recentrifuged at
12,000 rpm for 10min at 4∘C using an Eppendorf 5415D
centrifuge (Hamburg, Germany). The resulting clean super-
natants of heart tissue extracts were used for further esti-
mation of endogenous antioxidant enzymes including SOD,
GPx, GRx, and GST using standard ELISA micro-plate assay
kits. The levels of SOD, GPx, GRx, and GST were expressed
as units/mg of protein, nmol of NADPH oxidized/min/mg
of protein, nmol of NADPH oxidized/min/mg of protein,
and nmol of CDNB conjugated/min/mg of protein, respec-
tively. The total protein in the heart tissue homogenates was
estimated by the method described by Lowry et al. [25].
Briefly, 0.2mL sample (digested with 0.1 N sodium hydroxide
(NaOH)) wasmixed with 2mL of working reagent (amixture
of 2% sodium carbonate, 0.1 NNaOH, 1.56% copper sulphate,
and 2.37% sodium-potassium tartrate), and the reaction
mixture was incubated for 10min at room temperature. The
addition of 1 N Folin-Ciocalteu’s phenol reagent (0.2mL)
was followed by a 30min incubation at room temperature.
Finally, the absorbance was measured at 660 nm. Bovine
serum albumin was used as the standard to calculate the
protein content of samples.
2.8. Histopathological Examination. After sacrificing the ani-
mals, the hearts were rapidly dissected and immediately
washed with saline before being fixed in 10% formalin. The
fixed tissues were then embedded in paraffin.After that, serial
sections (5 𝜇m thickness) were cut followed by staining with
hematoxylin and eosin (H & E). Microscopic observation
was done using a fluorescence microscope over normal
spectra (Olympus DP72, Tokyo, Japan) at 40x magnification.
Photomicrographs were taken by using an attached digital
camera. A dedicated pathologist who was blind to the treat-
ment assignment of the different study groups was assigned
to perform the histopathological evaluation.
2.9. Statistical Analysis. The results of all the groups are
shown as mean values ± standard deviations (SD). The data
was analyzed using SPSS (Statistical Packages for Social
Science, version 20.0, IBM Corporation, New York, USA)
and Microsoft Excel 2007 (Redmond, Washington, USA).
Statistical analyses of biochemical data were performed using
a one-way ANOVA followed by a Tukey post hoc test.
A 𝑝 value of <0.05 was accepted as indicating statistical
significance.
3. Results
None of the rats died in any of the experimental groups over
the entire 4-week treatment period. There was no significant
difference in the body weights observed at the baseline time
point or at the end of the experimental period between
the groups (Table 1). However, the heart weights increased
significantly (𝑝 < 0.05) in ISO-treated rats when compared
with normal control rats. When compared to ISO group, rats
pretreated withWSLEt had a significant (𝑝 < 0.05) reduction
in heart weight, indicating its cardioprotective effects. No
significant differencewas observed in rats treatedwithWSLEt
alone when compared to normal control rats.
Rats treated with ISO alone had a marked (𝑝 < 0.05)
elevation in serum cTnI levels when compared to the control
(Figure 2). However, oral pretreatment of WSLEt for 4 weeks
significantly (𝑝 < 0.05) decreased serum cTnI levels in ISO-
treated rats when compared with ISO group.
A marked increase in the activities of serum cardiac
enzymes was observed in ISO-induced myocardial ischemic
rats (Figure 3). This effect was significantly ameliorated by
WSLEt.
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Table 2: WSLEt ameliorates the oxidative damage caused by ISO as demonstrated by the changes in the serum lipid profiles.
Parameters Group
Sham WSLEt + Sham WSLEt + ISO ISO
TC (mg/dL) 50.19 ± 6.34a 45.67 ± 4.93a 56.37 ± 6.38b 74.75 ± 12.35c
TG (mg/dL) 42.69 ± 5.55a 38.46 ± 8.09a 67.56 ± 8.90b 82.29 ± 6.12c
VLDL-C (mg/dL) 8.54 ± 1.11a 7.69 ± 1.39a 12.33 ± 1.41b 16.46 ± 1.22c
HDL-C (mg/dL) 45.12 ± 2.71a 49.12 ± 4.49b 46.04 ± 1.15ab 19.89 ± 1.21c
Results are expressed as mean values ± SD; 𝑛 = 10. a,b,cValues in the same row that do not share superscript letters (a, b, c) differ significantly at 𝑝 < 0.05.
Table 3: WSLEt ameliorates the oxidative damage caused by ISO as demonstrated by the changes in LPO levels and the activities of SOD,
GRx, GPx, and GST.
Parameters Group
Sham WSLEt + Sham WSLEt + ISO ISO
LPO (nmol TBARS/mg of protein) 42.77 ± 1.05a 37.18 ± 1.85a 40.02 ± 1.17a 82.17 ± 1.35b
SOD (units/mg of protein) 1.45 ± 0.02ab 1.58 ± 0.16a 0.33 ± 0.02b 0.10 ± 0.00c
GRx (nmol NADPH oxidized/min/mg of protein) 97.56 ± 2.09a 90.57 ± 1.79a 97.14 ± 6.05a 75.59 ± 9.79b
GPx (nmol NADPH oxidized/min/mg of protein) 2.15 ± 0.45a 3.12 ± 0.16b 1.98 ± 0.00ab 0.96 ± 0.00c
GST (nmol of CDNB conjugated/min/mg of protein) 2.04 ± 0.06a 4.05 ± 0.19b 1.99 ± 0.11a 0.85 ± 0.02c
Results are expressed as mean values ± SD; 𝑛 = 10. a,b,cValues in the same row that do not share superscript letters (a, b, c) differ significantly at 𝑝 < 0.05.
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Figure 2: WSLEt ameliorates the oxidative damage caused by ISO
as demonstrated by the changes in cTnI levels. Bars represent
mean values ± SD (𝑛 = 10); bars with different letters represent
significantly different mean values at 𝑝 < 0.05. ND: not detected.
Similarly, pretreatment with WSLEt also ameliorated
serum lipid profile increases (TC, TGs, VLDL-C, and HDL-
C) (Table 2).
The activities of antioxidant enzymes such as SOD, GRx,
GPx, GST, and LPO in the hearts of ISO-treated rats, which
were significantly decreasedwhen comparedwith the control,
improved significantly by pretreatmentwithWSLEt (Table 3).
Figures 4(a)–4(d) show the effects of WSLEt on the his-
tology of the heart in normal and ISO-induced myocardial-
infarcted rats. Control rats and those treated with WSLEt
(100mg/kg) showed normal cardiac fibers (Figures 4(a) and
4(b)) with no overt damage observed. Figure 4(d) shows
an ISO-treated myocardium with an area of infarction with
splitting of cardiac muscle fibers, edematous intramuscular
space, and inflammatory cells. Animals from WSLEt + ISO,
however, had cardiac muscle fibers with significantly fewer
inflammatory cells (Figure 4(c)).
4. Discussion
To our knowledge, our study is the first to demonstrate the
cardioprotective effect of WSLEt. The experimental animal
hearts revealed a significant increase in both their absolute
and relative weights following ISO administration, although
the body weight remained relatively unchanged.The increase
in heart weight may be due to increased water accumulation
with edematous intramuscular spaces in heart tissue and
increased protein content [10], which is also confirmed by
the histopathological findings. It has been proposed that
myocardial function may be reduced by approximately 10%
due to an increase in myocardial water content by 1% [26].
Increased membrane permeability in the pathogenesis of
cardiac muscle cell injury following catecholamine toxicity
is purported to be one of the main contributing factors
to water accumulation in the heart [11]. Catecholamines
are important regulators of myocardial contractility and
metabolism. However, it has been long known that excess
levels of catecholamines are responsible for cellular damage,
as observed in clinical conditions such as angina, tran-
sient myocardial hypoxia, acute coronary insufficiency, and
subendocardial infarct. The administration of ISO has effects
on mitochondrial LPO, antioxidants, TCA cycle enzymes,
and respiratory marker enzymes. Animals develop infarct-
like lesions when injected with ISO, a potent synthetic
catecholamine [27]. Increased generation of cytotoxic free
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Figure 3: WSLEt ameliorates the oxidative damage caused by ISO as demonstrated by the changes in the cardiac marker enzyme activities.
(a) The effects of WSLEt on CK-MB and LDH levels and (b) the effects of WSLEt on AST and ALT levels. Bars represent mean values ± SD
(𝑛 = 10); bars with different letters represent significantly different mean values at 𝑝 < 0.05.
radicals as a result of the autooxidation metabolic products
of ISO is one of the well-recognized mechanisms of ISO-
induced myocardial necrosis [28]. Pretreatment withWSLEt,
however, significantly decreased the absolute and relative
heart weights, bringing them close to their normal values,
which indicates the protective effect of the WSLEt on the
myocardium against infiltration or accumulation with water.
Cardiac troponin is a low molecular weight protein
which is a constituent of the myofibrillary contractile appa-
ratus of the cardiac muscle. cTnI has been shown to be
a highly sensitive and specific marker of myocardial cell
injury; it is usually absent in serum in normal individuals
and released only after myocardial necrosis [29]. In this
study, an increased level of serum cTnI in ISO-treated rats
was observed relative to the control group. The increased
level of cTnI may be attributed to the ISO-induced cardiac
damage. Animals treated with ISO following pretreatment
with WSLEt, however, exhibited a significant reduction in
cTnI levels when compared to ISO-treated rats without the
WSLEt pretreatment. Our results are consistent with those
from a previous study reported by Priscilla and Prince [14].
Pretreatment withWSLEt significantly decreased serum cTnI
levels in ISO-treated cardiotoxic rats. It is assumed that
WSLEt may preserve the structural and functional integrity
of the contractile apparatus, which prevents cardiac damage
and leakage of troponins from the heart into the blood.
Nevertheless, further research is essential to elucidate the
exact mechanisms underlying the cardioprotective effect of
WSLEt.
The myocardium contains high concentrations of diag-
nostic markers of MI; once it is metabolically damaged, it
releases its contents into the extracellular fluids [30].Of all the
macromolecules leaked from the damaged tissue, myocardial
enzymes are the best markers of tissue damage because of
their tissue specificity and catalytic activity.Whenmyocardial
cells are damaged or destroyed due to a deficiency in the
oxygen supply or glucose, the cardiac membrane becomes
permeable or may rupture entirely, resulting in the leakage
of enzymes [14]. The activity assay for CK-MB in serum is
an important diagnosis because of the marked abundance
of this enzyme in myocardial tissue and its virtual absence
from most other tissues and its consequent sensitivity. CK-
MB isoenzyme activity is useful as an index for the early
diagnosis of not only myocardial infarction, but also any type
of myocardial injury. Leakage of cytosolic enzymes including
CK-MB, LDH, AST, and ALT (which serve as diagnostic
markers from the damaged tissue) into the blood stream
may occur when cell membranes become more permeable
or rupture. The amounts of these cellular enzymes in the
serum reflect the alterations in plasma membrane integrity
and/or permeability [8]. Furthermore, the amount of the
enzymes appearing in serum is reported to be proportional
to the number of necrotic cells [31], which also reflects
a nonspecific alteration in the plasma membrane integrity
BioMed Research International 7
(a) (b)
(c) (d)
Figure 4: (a) Sham group: normal control heart showing normal cardiac muscle fibers. (b)WSLEt + Sham group:WSLEt-treated (100mg/kg)
heart showing normal muscle fibers without any pathological changes. (c) WSLEt + ISO group: WSLEt-treated (100mg/kg) + ISO-treated
(85mg/kg) heart showing no edematous intramuscular space and fewer inflammatory cells (black arrows). (d) ISO group: ISO-treated
(85mg/kg) heart showing cardiac muscle fibers with muscle separation (green arrows), edematous intramuscular space (red arrows), and
inflammatory cells (black arrows).
and/or permeability as a response to 𝛽-adrenergic stimula-
tion [16]. In the present study, rats administered with ISO
showed significant increases in the levels of all these marker
enzymes in serum, in line with the results from previous
reports, indicating ISO-induced necrotic damage of the
myocardium and leakiness of the plasma membrane [14, 22,
32]. Pretreatment with WSLEt, however, resulted in lowered
activities of all marker enzymes in the serum, indicating that
WSLEt helps in maintaining the membrane integrity, thereby
restricting the leakage of these enzymes. Phenolic acids such
as gallic acid, syringic acid, vanillic acid, and p-coumaric
acid and flavonoids such as catechin and naringenin are
important constitutive antioxidants found inWSLEt, as in our
study and that reported by Alam et al. [5]. Tanvir et al. [33]
and Afroz et al. [34] speculated that antioxidant compounds
present in their sample confer protective effects on liver by
preserving the membrane integrity. Therefore, it is plausible
that the presence of these antioxidants may help protect
against oxidative cardiac injury, thus restricting the leakage of
these enzymes from themyocardium. For instance, Arts et al.
[18] evaluated the effects of catechin intake on the health risks
of high levels of body fat and the incidence of IHD and stroke
in a cohort of elderly men; according to the study, catechin,
whether from tea or other sources, may reduce the risk of
IHDmortality. It is suggested that flavonoids decrease the risk
of CDV by improving coronary vasodilation, decreasing the
ability of platelets in the blood to clot, and preventing low-
density lipoproteins from oxidizing [35].
Lipids play an important role in CVD, not only by
contributing to the development of atherosclerosis but also
by modifying the composition, structure, and stability of the
cellular membrane. High levels of circulating cholesterol and
its accumulation in heart tissue have been associated with
cardiovascular damage [36]. Rats treated with ISO showed a
significant increase in serum levels of TC, TGs, and VLDL-
C, as previously reported [37]. Generally, the mechanism
of actions of lipolytic hormones, including ISO, on fat
cells are believed to be mediated by the cAMP cascade, in
which lipolytic hormones activate adenylate cyclase, thereby
increasing cAMP formation. Subsequently, cAMP promotes
lipolytic activity by activating cAMP-dependent protein
kinase, which phosphorylates hormone-sensitive lipase [38].
This results in the hydrolysis of stored triacylglycerol, which
may contribute to hyperlipidemia [39]. High levels of LDL-
C and VLDL-C have been positively correlated with MI but
are negatively correlated with HDL-C. HDL-C inhibits the
uptake of LDL-C by the arterial walls and facilitates the
transport of cholesterol from peripheral tissues to the liver,
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where it is catabolized and excreted from the body [40].
Pretreatment with WSLEt, however, significantly amelio-
rates these changes, thereby maintaining the normal fluidity
and function of the myocardial membrane. Polyphenols,
particularly gallic acid and catechin, have been reported
to inhibit cholesterol esterase [41]. In general, pancreatic
cholesterol esterase plays an important role in hydrolyzing
dietary cholesterol esters, which liberates free cholesterol in
the lumen of the small intestine [42].Therefore, the inhibition
of cholesterol esterase is expected to limit the absorbance of
dietary cholesterol, resulting in reduced cholesterol absorp-
tion. Moreover, polyphenols can also bind with bile acids to
increase their fecal excretion, which has been hypothesized as
a possible mechanism for the lowering of plasma cholesterol
levels by polyphenols [41].
LPO is a well-established mechanism of cellular injury
and has been used as an indicator of oxidative stress that
leads to the pathogenesis of MI [7]. The degree of LPO
has been evaluated by estimating TBARS, lipid hydroxides,
and the presence of conjugated dienes [7]. Lipid peroxide-
mediated myocardial damage has been observed in ISO-
treated myocardial-infarcted rats. The myocardial necrosis
observed in the rats receiving ISO can be attributed to
peroxidative damage, as it has been previously reported
that ISO generates lipid peroxides [43]. In our study, ISO
treatment resulted in a significant increase in the levels of
LPOproducts in the heart tissue. Increased LPOappears to be
the initial stage of the pathogenesis making heart tissue more
susceptible to oxidative damage. WSLEt pretreatment signif-
icantly reduces the levels of lipid peroxides in ISO-treated
rats. Thus, it is plausible that some constituents present in
WSLEt with antioxidant activities scavenge the LPO products
produced excessively by ISO and confer protection to the
cardiac tissue.
The oxidative stress may be exerted through quinone
metabolites of ISO that react with oxygen to produce super-
oxide anions and other reactive oxygen species (ROS) that
interfere with antioxidant enzymes [19]. The presence of the
endogenous antioxidant enzymatic defense is highly impor-
tant for the neutralization of oxygen-free-radical-mediated
tissue injury [44]. SOD, catalase (CAT), and GPx, which are
the primary free radical scavenging enzymes, are involved
in the first-line cellular defense against oxidative injury,
decomposing oxygen (O
2
) and hydrogen peroxide (H
2
O
2
)
before their interaction to form the more reactive hydroxyl
radical [45]. In this study, significantly lower activities of
SOD and GPx were observed in the heart tissues of ISO-
treated rats when compared to control rats. The observed
decreases in the activities of these enzymes may be due
to their increased utilization for scavenging ROS and their
inactivation by excessive ISO oxidation [16]. Treatment with
WSLEt, however, improved the activities of SOD and GPx
by scavenging superoxide and H
2
O
2
produced by ISO. The
two enzyme levels were also higher in WSLEt alone treated
group when compared with the control group which is a clear
indication thatWSLEt not only scavenges the oxidative stress
but also boosts the activity of few antioxidant enzymes during
normal physiological conditions. GRx is an antioxidant
enzyme involved in the reduction of GSSG (an end product
of the GPx reaction) to GSH [21].
In ISO-treated rats, there was a marked reduction in
GPx activity, leading to a reduced availability of substrate
for GRx, thereby decreasing its activity. Oral treatment with
WSLEt in ISO-treated rats restored the activity of GRx,
which accelerates the conversion of GSSG to GSH. A phase
II enzyme such as GST not only catalyzes the conjugation
of both hydroquinones and epoxides of polycyclic aromatic
hydrocarbons with GSH for their excretion, but also shows
lower activity towards organic hydroperoxides for their
detoxification from cells/tissues [19]. In ISO-treated rats,
there was a marked reduction in GST activity, but the activity
of this phase II enzyme was restored in WSLEt-treated
rats. More interestingly GST levels doubled in WSLEt alone
treated group; that is, WSLEt can show a strong potential to
enhance GST activity in healthy individuals. It is plausible
that the upregulation of the activity or expression of Nrf2, a
transcription factor released from its repressor (Keap1) under
oxidative or xenobiotic stress [46], is considered as possible
mechanism through which WSLEt pretreatment restores
antioxidant enzyme functions as also suggested by Erejuwa
et al., 2011 [47]. The released Nrf2 binds to the antioxidant
response element of cytoprotective genes and induces their
expression as well as the subsequent expression of free radical
scavenging enzymes to neutralize and eliminate the cytotoxic
oxidants [46].
A histopathological examination of the myocardial tis-
sue of normal control rats clearly illustrated the integrity
of the myocardial cell membrane. The histopathology of
the WSLEt-pretreated myocardial-infarcted heart samples
showed a near normalmorphology of cardiacmuscle with the
absence of necrosis when compared to ISO-treated samples
without WSLEt pretreatment, which further confirms the
biochemical findings. Similar histopathological findings were
observed in ISO-treated rats for gallic acid [14], which also
has strong antioxidant properties. Overall, the results of this
study offer scientific evidence of the importance of WSLEt
in cardioprotection against CVD, a set of diseases whose
pathogenesis has long been associated with oxidative stress.
Further studies should be conducted to elucidate the exact
mechanism of the cardioprotective effect of WSLEt.
5. Conclusion
The present biochemical and histopathological findings con-
firm that WSLEt preserves the integrity of myocardial cell
membrane by maintaining the activities of cTnI and marker
enzymes in the serum and heart of ISO-treated cardiotoxic
rats. This may be due to the antilipoperoxidative and antiox-
idant effects of WSLEt. We conclude thatW. somnifera leaves
have the potential to be used as cardioprotective agents by
protecting cardiac tissue against oxidative damage.
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